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Abstract
Background: Worldwide cervical cancer remains a leading cause of mortality from gynecologic
malignancies. The link between cervical cancer and persistent infection with HPV has been
established. At a molecular level little is known about the transition from the precancerous state
to invasive cancer. To elucidate this process, cervical biopsies from human specimens were
obtained from precancerous state to stage III disease.
Methods: Cervical biopsies were obtained from patients with a diagnosis of cervical cancer
undergoing definitive surgery or staging operation. Biopsies were obtained from patients with
precancerous lesions at the time of their excisional procedure. Control samples were obtained
from patients undergoing hysterectomy for benign conditions such as fibroids. Samples were
subjected to proteomic profiling using two dimensional gel electrophoresis with subsequent trypsin
digestion followed by MALDI-TOF protein identification. Candidate proteins were then further
studied using western blotting, immunoprecipitation and immunohistochemistry.
Results: Annexin A1 and DNA-PKcs were found to be differentially expressed. Phosphorylated
annexin A1 was up regulated in diseased states in comparison to control and its level was strongly
detected in the serum of cervical cancer patients compared to controls. DNA-PKcs was noted to
be hyperphosphorylated and fragmented in cancer when compared to controls. By
immunohistochemistry annexin A1 was noted in the vascular environment in cancer and certain
precancerous samples.
Conclusion: This study suggests a probable role for protein tyrosine phosphorylation in cervical
carcinogenesis. Annexin A1 and DNA-PK cs may have synergistic effects with HPV infection.
Precancerous lesions that may progress to cervical cancer may be differentiated from lesions that
will not base on similar immunohistochemical profile to invasive squamous cell carcinoma.
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Introduction
Worldwide cervical cancer remains the second leading
cause of cancer mortality in females [1]. The five year sur-
vival for locally advanced cervical cancer is within the
range of 18% to 34% [2,3]. This poor prognosis and lack
of treatment for late stage and recurrent disease probably
reflects the sparse understanding of the molecular patho-
genesis of disease progression. The link between cervical
cancer and the Human Papilloma Virus (HPV) has long
been established. However, the multi-step progression in
cervical carcinogenesis from the precancerous lesions of
high grade cervical intraepithelial neoplasia (high grade
dysplasia) to invasive carcinoma is still to be elucidated.
Unlike colon cancer which has a definite precancerous
state and an elucidated model for carcinogenesis, cervical
carcinogenesis with a known precancerous lesion has not
yet been completely elucidated.
In general, at a molecular level cancer is considered a state
of altered signaling. One of the most common mecha-
nisms of activating and/or inactivating signaling pathways
is phosphorylation and de-phosphorylation at serine,
threonine and tyrosine residues. This modification con-
trols a variety of cellular processes including cellular
growth, proliferation, cell cycle control, cytoskeletal
mobility and receptor regulation [4]. Phosphorylation
leads to allosteric modifications that may result in suffi-
cient conformational change to cause activation or inacti-
vation of various proteins and associated altered
functioning. We hypothesized that identification of phos-
phoproteins associated with the various stages of cervical
cancer may provide information on the mechanism of
tumorigenesis and insight in the development of diagnos-
tic and therapeutic procedures.
The mitogen activated protein kinase (MAPK) pathways
are known be deregulated in many human malignancies
[5]. The best studied with regards to malignancy are the
extracellular signal regulated protein kinases (ERK). ERKs
phosphorylate cytoplasmic targets or migrate to the
nucleus where they can activate transcription factors
involved in cellular proliferation. Aberrant signaling in
the MAPK/ERK has been described in prostate; breast and
colon cancers in in vitro as well as in vivo model [6-8]. In
cervical cancer, one study has described decreased activa-
tion of ERK1/2 in invasive cervical carcinoma [9].
Annexin A1 is a calcium dependent phospholipid binding
protein that has been linked to membrane trafficking
through exocytosis and endocytosis [10]. Other studies
have evaluated its role in the modulation of the MAPK/
ERK [11]. Many members of the Annexin family are
known to undergo alternate splicing yielding a number of
isoforms. The resultant variant forms may have different
functions and binding capacity compared to the native
forms [12].
DNA-Protein Kinase catalytic subunit (DNA-PKcs), a mac-
romolecule found to be involved in the repair of double
stranded DNA breaks through activation of p53 was
found to be expressed in cancer specimens in its tyrosine
phosphorylated and cleaved form [13]. In contrast, in
normal specimens DNA-PKcs existed in its intact full
length non-phosphorylated form.
The aim of the study was to identify differential expression
and modification of proteins that could suggest aberrant
pathways which could serve as novel targets for develop-
ing new therapies in the treatment of cervical cancer and
in monitoring disease recurrence or progression.
Materials and methods
Antibodies
Annexin A1 mouse monoclonal (Santa Cruz, CA, USA),
Calgranulin A8 rabbit polyclonal (Santa Cruz, CA, USA),
DNA-PK catalytic subunit, multiple clones (USBiological,
MA, USA). Phospho-ERK44/42 (Cell Signaling, Beverly,
MA), Phospho-MEK (Cell Signaling, Beverly, MA, USA),
MEK (Cell Signaling, Beverly, MA, USA), Phosphotyrosine
mouse monoclonal antibody (Santa Cruz, CA, USA), p53
rabbit polyclonal antibody (Santa Cruz, CA, USA), Goat
Anti-mouse secondary HRP (Alpha Diagnostics, San
Antonio, TX, USA), Anti-rabbit IgG HRP secondary (Alpha
Diagnostics, San Antonio, TX, USA).
Buffers
Buffer M (100 mM HEPES-KOH, pH 7.4, 5 mM EGTA, 20
mM EDTA, 100 mM sodium orthovanadate, 0.5 M
sodium fluoride, 10 mM sodium molybdate, 0.2 M β-
glycerophosphate); 2-D Lysis Buffer (8 M urea, 4%
CHAPS); Rehydration Buffer (8 M Urea, 2% CHAPS,
0.002% bromophenol blue, 0.75% pH 4–7 pharmalyte);
Equilibration Buffer (50 mM Tris-HCL, pH 8.8, 6 M Urea,
30% of 87% Glycerol, 2% SDS, 0.002% Bromophenol
blue); Transfer Buffer (25 mM Tris, 200 mM Glycine, 20%
Methanol);
TBS-T (10 mM Tris pH 7.4, 154 mM sodium chloride,
0.1% Tween 20); Blocking Buffer (5% carnation nonfat
dried milk or 5% BSA with phosphatase inhibitors for
phosphoamino antibodies). 3× Sample Buffer (187.5 mN
Tris-HCL, 6% SDS, 30% Glycerol, 150 mM DTT, 0.3%
bromophenol blue).
Patients
After obtaining IRB approval and written consents,
patients were recruited from the University of Texas Med-
ical Branch after having a biopsy proven diagnosis of high
grade dysplasia (pre-cancer) or frankly invasive cervicalJournal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
Page 3 of 10
(page number not for citation purposes)
cancer at different stages. A small biopsy was obtained
from these patients. The patients' ages ranged from 16–69
years old; and the most advanced stage recruited was IIIB
disease. Normal cervical tissue was obtained from women
undergoing hysterectomy for benign diseases such as
fibroids or endometriosis without a history of abnormal
Pap smears. The study cohort consisted of normal (n =
10), precancerous (n = 10), stage I (n = 6), stage II (n = 6)
and stage III (n = 5).
Tissue processing
Biopsy specimens were collected in a commercially pre-
pared solution of RNA later (Ambion, Austin, TX, USA) in
the operating room and then stored at -80°C until further
processing. The specimens were subsequently rinsed in
PBS, minced in Buffer M and homogenized in the same
medium using a polytron at full speed and subsequently
centrifuged at 13,000 rpm for 10 minutes. Protein quanti-
fication was performed on the supernatant using the Brad-
ford Assay (BioRad reagent). Aliquots of 100 μg and 200
μg were then stored at -80°C to minimize the effects of tis-
sue freeze thawing. In each analysis individual patient
samples were used and not pooled.
Two dimensional gel electrophoresis (2D-GE) and MS 
sequencing and 1D SDS-PAGE
Aliquots of cell lysates (200 μg) were diluted with rehy-
dration buffer and 3.2 μl of 1 M DTT. pH 4–7 IPG immo-
biline dry strips were rehydrated with 200 μl of a
combined mixture of sample at 20°C for 12 hours. Iso-
electric focusing was performed for a total of 18000 Vh.
IPG strips were subsequently incubated in equilibration
buffer at room temperature on an orbital shaker for 15
minutes. Samples were then separated by SDS-PAGE in
the second dimension on 10–20% Tris-Glycine BioRad
precast gels.
Gels prepared for Matrix Laser Desorption Ionization –
Time of Flight Mass Spectrometry (MALDI-TOF MS) were
stained using GelCode Blue Stain Reagent from Pierce
Biotechnology. The gel pieces were then trypsin digested
and proteins were identified by MS fingerprinting of pep-
tides using ProFound data search.
Immunoprecipitation and co-immunoprecipitation
Aliquot of cell lysates (200 μg) from normal, pre-cancer-
ous and cancerous specimens were incubated with Protein
G Sepharose beads (Sigma-Aldrich,) for 2 hours at 4°C for
pre-clearing. Beads and protein mixtures were then centri-
fuged at 13,000 rpm for 1 minute. Aliquots of 4 μl anti-
body were added to supernatant in fresh microfuge tube
and incubated with constant rotation for 4 hours at 4°C.
Fresh beads were then added and the mixture was allowed
to rotate overnight at 4°C. The beads were then collected
after centrifugation and were washed three times with 500
μl of PBS. 100 μl of 3× sample buffer was added to immu-
nopellets which were then boiled for 5 minutes. Mixtures
were centrifuged at 13,000 rpm for 2 minutes and the
supernatant collected. 15 μl aliquots of the supernatant
were then subjected to separation by SDS-PAGE on 5% or
4–20% Tris-Glycine precast BioRad gels.
Western blotting
Tissue lysates and immunoprecipitates were prepared as
described above and subsequently transferred to PVDF
membranes. Membranes were blocked for 1 hour in 5%
non-fat dry milk in 0.1% Tween 20 in TBS (pH7.4). Pri-
mary antibodies were diluted in 5% nonfat dry milk, 0.1%
Tween 20 in TBS and incubated at 4°C overnight. Mem-
branes were washed in 0.1% Tween 20 in TBS. Secondary
horseradish peroxidase (HRP) antibody was diluted
1:4000 in non fat dry milk in 0.1% Tween 20 and incu-
bated for 1 hour at room temperature. Membranes were
washed and incubated with HRP chemiluminescence rea-
gents from Millipore (Billerica, MA, USA) and developed
after exposure to Biomax ML film. Loading controls were
derived from stained Coomasie gels.
Immunohistochemical analysis
Buffered formalin-fixed, paraffin-embedded tissue sec-
tions (5 μm) were deparaffinized and rehydrated by pas-
sage through xylene and graded ethanol solutions. Slides
were then treated with 3% hydrogen peroxidase with
0.03% sodium azide in PBS for 10 min, followed by
microwave antigen retrieval at 100°C for 10 min in
DAKO Target Retrieval Solution (DAKO Corporation,
Carpinteria, CA) in a H2800 Microwave Processor (Energy
Beam Sciences, Inc; Agawam, MA). Slides were incubated
in 0.05% casein (Sigma, St. Louis, MO)/0.05% Tween-20
(DAKO Corporation, Carpinteria, CA)/PBS for 30 min to
block nonspecific protein binding. Mouse monoclonal
antibody, Annexin AI (Santa Cruz Biotechnology Inc,
Santa Cruz, CA) was applied to sections at a 1:400 dilu-
tion for 60 min. Mouse IgG Ready-To-Use (InnoGenex,
San Ramon, CA) was used as a negative control. DAKO
EnVision+ System-HRP Labeled Polymer Anti-mouse
(DAKO Corporation, Carpinteria, CA) served as the detec-
tion system, and colorized by DAB (DAKO Corporation,
Carpinteria, CA). Slides were counter-stained with
Mayer's Modified Hematoxylin (Poly Scientific, Bay
Shore, NY) before mounting, viewed under an Olympus
BX51 microscope and images recorded by DP70 Digital
Camera (Olympus Optical Co., Ltd; Tokyo, Japan).
PF2D serum fractionation and western blotting
Protein fractionation 2D profiling is a HPLC system devel-
oped by Beckman which separates proteins based on two
dimensional HPLC. First proteins are separated by their
iso-electric points in the first dimension. Fractions were
then collected in 96 well plates and are re-injected into aJournal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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second dimension reverse phase column and separated
based on hydrophobicity and again collected in 96 well
plates.
Whole blood was centrifuged at 3,000 × g and 100 μl aliq-
uots of serum were buffer exchanged in Beckman start
buffer (proprietary). Protein quantification was done
using the Bicinchoninic assay and 2–5 mg of serum was
injected in Beckman PF2D HPLC System for fractiona-
tion. Fractions were collected in 96 well plates in the first
and second dimension. Proteins were then transferred to
PVDF membranes via the Biomek 2000 robot and a Sch-
leicher & Schuell dot blotting apparatus and subsequent
western blotting performed in the manner described
above.
Results
Identification of annexinA1 by 2DGE/MALDI-TOF with 
validation by immunoblotting
Annexin A1 was identified by MALDI-TOF MS after in gel
trypsin digestion to be differentially expressed in cancer
samples compared to controls when 2D gels were com-
pared. Once this candidate protein was found then its
presence was validated by western blotting (Figure 1).
32 kD annexin A1 is differentially tyrosine phosphorylated 
in cervical cancer compared to normal
To determine if the annexin A1 expressed in the cancerous
state was phosphorylated, immunoprecipitation with
phosphotyrosine antibody was carried out followed by
western blotting with annexin A1 monoclonal antibody.
38 kD and 32 kD bands were identified. There was an
obvious up-regulation of the modified 32 kD protein
noted with disease progression. The expression of the 38
kD phosphotyrosine form was less specific for disease
progression (Figure 2). The reverse immunoprecipitation
was carried out with annexin followed by western blotting
with phosphotyrosine antibody and similar results were
obtained (data not shown).
Differential expression and localization of Annexin A1 in 
cancer specimens compared to controls
The endothelial lining of the vascular spaces in cancer tis-
sues exhibited annexinA1 staining in contrast to weak or
absent staining in control samples (Figure 3A and 3B).
Characteristic two dimensional gel demonstrating protein expression in cervical cancer form tissue lysate Figure 1
Characteristic two dimensional gel demonstrating protein expression in cervical cancer form tissue lysate. The left panel shows 
the entire proteome in a stage II cancer specimen. Western blotting with monoclonal annexin A1 showed two distinct spots as 
depicted in panel B.Journal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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Complementary to this was the observation that by chro-
matographic separation using the Beckman PF2D Pro-
teome Lab annexin A1 was strongly expressed in the sera
of cervical cancer patients and was absent in sera of a
cohort of unexposed aging nuns (Figure 3C). With pro-
longed exposure of the film, weak staining was observed
in the sera of some patients with pre-invasive disease
(data not shown).
Aberration in MAPK/ERK pathway with disease 
progression and co-migration with annexin A1
Previous studies have shown that annexin A1 specifically
target the MAPK/ERK pathway at a site upstream of MEK1/
2 [11]. Therefore, we sought to investigate the expression
of ERK1/2 with disease progression and to analyze if its
expression would be linked to annexin A1 expression.
Total ERK1/2 and MEK1/2 demonstrated up-regulation
with advancing disease stage. Of interest MEK2 and ERK2
were consistently absent in the normal samples studied.
The phosphorylated activated forms of MEK 1/2 and ERK
1/2 showed a stronger fold change in expression with
advancing disease (Fig. 4). Additionally, annexin A1 was
shown to be in complex with activated pERK and pMEK
(data not shown).
Validation of DNA-PKcs and differential tyrosine 
phosphorylation with advancing disease
Phosphotyrosine immunoprecipitate was analyzed by
2DE. In gel digestion of candidate spot identified DNA-
PKcs as a modified protein. Western blot analyses on 2DE
using mouse monoclonal DNA-PKcs specific antibody
confirmed the presence of a large multi-subunit protein.
The pattern of resolution by iso-electric points was differ-
ent in cancer compared to normal (Figure 5A). The 350
kD full length protein detected in normal and precancer-
ous specimen was not significantly phosphorylated. In
contrast, in invasive cancer tissues, the full length protein
as well as a 250 kD and 170 kD fragments were consist-
ently detected as being hyperphosphorylated at tyrosine
residues (Figure 5B). By immunoprecipitation and west-
ern blot we demonstrated that in cervical cancer speci-
mens DNA-PKcs failed to bind to p53 (data not shown).
Calcium binding protein and tyrosine modification in 
cervical cancer
By 2DGE multiple S100 calcium binding proteins were
shown to be modified by tyrosine phosphorylation, in
particular S100A8 and S100A9. After identification by
MALDI-TOF, tissues were then subjected to SDS-PAGE
and western blotting with specific antibodies. Calgranulin
A8 did show differential expression with disease progres-
sion. Consistently, the protein was identified in its
unmodified form in normal tissue. However, even at the
precancerous states the protein was noted to be tyrosine
phosphorylated (Figure 6).
Discussion
While the incidence of abnormal Pap smears and dyspla-
sia is very high, only 1–2% of true precancerous lesions
will progress to invasive cancer. The issue that begs to be
addressed is the distinguishing feature(s) between the
lesions that will progress and those that will not. The aim
of our study was to gain a more complete understanding
of cervical tumorigenesis at the molecular level using tyro-
sine phosphoproteomics. We hypothesize that patients
with high grade dysplastic lesions exhibiting annexinA1
in the serum and tumor vasculature will be at risk for dis-
ease progression since the identical pattern is seen in inva-
sive cancer. This theoretically could serve to differentiate
the true pre-cancerous lesions with potential of progress-
ing to invasive cervical cancer from those that will not.
Annexin A1 is a dual calcium and phospholipid binding
protein which has been implicated in inflammation and
numerous human cancers, including head and neck, pitu-
itary and prostate cancers [14,15]. It belongs to a family of
twenty such proteins with high structural homology in the
70 amino acid repeat sequence. The multifunctional prop-
erties and specificity of the molecule are mediated
through its N-terminal domain. Annexin A1 has been
shown to play critical roles in membrane trafficking
through endocytosis and exocytosis [10] as well as serve as
a scaffold protein in multi-protein complexes. It has also
been shown to be a major substrate for EGFR kinase [16].
Alldridge  et al showed that annexin A1 regulates the
MAPK/ERK pathway [11]. The MAPK/ERK when activated
Expression of annexin A1 with disease progression Figure 2
Expression of annexin A1 with disease progression. Immuno-
precipitation with phosphotyrosine antibody followed by one 
dimensional SDS-PAGE and western blot with annexin A1 
antibody. Two phosphorylated isoforms noted. 32 kD form 
correlates well with disease progression. (N = normal, CIS = 
pre-cancer or high grade dysplasia, I = stage I, II = stage II, III 
= stage III).Journal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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Immunohistochemical analysis of paraffin embedded slides (×400) Figure 3
Immunohistochemical analysis of paraffin embedded slides (×400). (A) Absent staining of microvasculature endothe-
lium in normal biopsy specimen. (B) Positive staining of endothelial cells lining microvasculature in cervical cancer specimen. (B) 
(C) Representative PF2D HPLC analysis followed by western blot with annexinA1 monoclonal antibody of serum from control 
patient (upper panel) demonstrating absence of annexinA1 compared to presence of annexinA1 in serum of patient with stage 
II cervical cancer (lower panel).
A
B
CJournal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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through phosphorylation is noted for its role in cell pro-
liferation. Tyrosine phosphorylation of annexin A1 has
been observed in pituitary carcinomas but not adenomas
[14]. Recently, annexin A1 translocation was noted in
esophageal squamous cell carcinoma [17]. In our study
we have identified two forms of annexin A1. The 32 kD
form was not detected on the 2DGE analysis but was seen
clearly on the immunoprecipitation followed by western
blot (Figure 1 and Figure 2). This is not unexpected as it is
known that immunoprecipitation significantly concen-
trate proteins present in whole lysates compared to 2DGE.
There is a trend toward upregulation of the 32 kD form of
the protein in disease states including precancerous states
compared to normal and seems to be more specific than
the 38 kD form which demonstrated heterogeneity. Smith
et al demonstrated that in human lung lavage fluid,
annexin A1 presented as a doublet (37/33 kD) by western
blotting. In that study, annexin A1 in neutrophils was the
cleaved 33 kd form while the intact 37 kD form was recov-
ered from the cell surface [18]. In human model of skin
inflammation the 33 kD form was prevalent [19]. Addi-
tionally, previous studies have shown that phosphoryla-
tion of annexin A1 makes it susceptible to proteolytic
degradation [20] and phosphorylation of the 32 kD form
results in its exocytosis [21]. Further studies by Wang et al
have shown that phosphorylation at the N-terminal
decreases association of annexin A1 to plasma membrane
because of its decreased affinity for calcium binding and
therefore requiring larger internal calcium concentrations
[22]. Additionally, in our study a number of calcium
binding proteins were found to be phosphorylated in pre-
cancerous specimens and invasive cervical cancer speci-
mens.
Previous studies have shown that annexin A1 antibody
has been found in the serum of patients with lung cancer
[23]. We have shown through liquid chromatography that
annexin A1 is present in the serum of patients with inva-
sive cervical cancer and certain precancerous specimens.
Additionally, by IHC the endothelial cells lining the vas-
culature in the microenvironment in cancer stained posi-
tive for annexin A1 but absent staining was noted in the
controls. We propose that in cervical dysplasia/pre-cancer
and invasive cancer, annexin A1 tyrosine phosphorylation
leads to its solubilization and subsequent extravasation in
serum as evidenced by its presence in tumor microvascu-
lature but not in microvascular environment in controls.
In addition, alteration in the function, probable loss of
tumor suppressor role of the native protein may occur as
a result of the phosphorylation. Tyrosine phosphoryla-
tion of annexin A1 may be essential in the malignant
transformation of squamous epithelium of the cervix.
While this expression is not specific to cervical cancer, in
a patient with no other underlying pathology annexin A1
expression in the serum maybe used as a marker for dis-
ease progression, recurrence or to monitor response to
therapy. The mechanism of secretion remains unclear but
may partially be due to its phosphorylation and subse-
quent cleavage. It has been reported that extracellular
annexin A1 through its attachment to formyl peptide
receptors may lead to inhibition of neutrophil extravasa-
tion to sites of inflammation [24]. This could potentially
explain a means whereby HPV escape immune surveil-
lance leading to persistent disease and ultimately invasive
cervical cancer.
Consistent with its role as a scaffold protein we have
shown annexin A1 to be in complex with MEK1/2, ERK1/
2. There was no difference in the expression of MEK1 or
ERK1 with disease progression; however, there was a
marked up-regulation in the activated forms of ERK2 and
its immediate upstream activator, MEK2 with disease pro-
gression. This pathway may be affected by the up-regula-
tion of phosphorylated annexin A1 and may play a role in
the carcinogenesis of cervical cancer through increase cel-
lular proliferation.
The link between annexin A1 and cervical cancer may
have clinical significance. In a recent study, annexin A1
antibody given to tumor bearing rats with advanced lung
cancer improved survival and decrease weight loss [25].
Expression of MAPK/MEK and MAPK/ERK with cervical can- cer progression by western blotting Figure 4
Expression of MAPK/MEK and MAPK/ERK with cervi-
cal cancer progression by western blotting. Tissue 
lysates were subjected to SDS-PAGE followed by western 
analysis with MEK1/2, pMEK1/2, ERK1/2 and pERK1/2. Phos-
phorylated forms of MEK1/2 and ERK1/2 are upregulated in 
cancer specimens. MEK2 and ERK2 are consistently not 
expressed in normal specimens.Journal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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Based on our observation, annexin A1 could potentially
serve as a target to image, monitor and treat cervical can-
cer, particularly in advance or recurrent cases where thera-
peutic options are presently limited.
Another protein that was noted to be modified by tyrosine
phosphorylation in cancer as well as in precancerous
states and also shown to co-immunoprecipitate with
annexin A1 is DNA-PKcs. In the presence of double
stranded DNA breaks (DSB), activated DNA-PKcs is
responsible for the activation of p53 through binding and
serine phosphorylation. Previous studies have shown that
DNA-PKcs may be inactivated by tyrosine phosphoryla-
tion [26,27]. Other studies have demonstrated that inacti-
vation of DNA-PKcs results in hyperplasia, dysplasia of
the intestinal mucosa in colon cancer [13]. HPV E6 viral
oncoprotein has been shown to bind to p53 and target it
for degradation by ubiquitination. In our study we have
demonstrated that DNA-PKcs has been modified by tyro-
sine phosphorylation in diseased states, coupled with its
fragmentation and hence presumed inactivation. This
therefore could represent a novel way by which p53 is
inactivated in cervical carcinogenesis and may be synergis-
tic with the well known inactivation mechanism through
the HPV E6 viral oncoprotein. Previous studies have
shown fragmentation and inactivation of DNA-PKcs by
polio virus or adenovirus but none have linked its inacti-
vation to HPV [28-31]. Further studies are therefore
needed to elucidate any interaction between HPV and
DNA-PKcs.
While our sample size may be insufficient to perform
power analyses, the trends observed deserves considera-
tion and additional studies. Potential biomarkers may be
present amongst these modified proteins as well as immu-
notherapeutic and dietary supplemental agents to treat
the disease in a cancer with very limited therapy in the
recurrent and advanced disease. Future studies will be
aimed at investigating phosphorylation at serine and thre-
onine sites in diseases states and control in an effort to
mine the phosphoproteome of cervical carcinogenesis.
DNA-PKcs expression by immunoprecipitation and western blot analysis Figure 5
DNA-PKcs expression by immunoprecipitation and western blot analysis. (A) Differential expression of DNA-PKcs 
in cancer compared to normal. Demonstrated by anti-DNA-PKcs antibody 2DGE suggests a macromolecule with multiple frag-
ments and shift in iso-electric point in cancerous samples. (B) Immunoprecipitation with phosphotyrosine antibody followed by 
western blot with DNA-PKcs, showing fragmentation of molecule as early as high grade precancerous lesion.Journal of Carcinogenesis 2008, 7:2 http://www.carcinogenesis.com/content/7/1/2
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Conclusion
In this study we have demonstrated that there is a trend
toward upregulation of the tyrosine modified proteins,
Annexin A1, DNA-PKcs and certain calcium binding pro-
teins in cancer specimen in contrast to normal. We have
also demonstrated that a subset of patients with precan-
cerous disease demonstrate similar protein expression
and modification as in the invasive cancer. Based on the
data provided it may be feasible to distinguish precancer-
ous lesions with true invasive potential from those that
are less likely to progress to invasion. Annexin A1 expres-
sion.
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